GANX

Gain Therapeutics, Inc. Common Stock

1.84

USD

-0.11

-5.64%

Sep 23, 15:53 UTC -4

Closed

After-Market

1.88

+0.04

+2.17%

GANX Earnings Reports

Positive Surprise Ratio

GANX beat 13 of 22 last estimates.

59%

Next Report

Date of Next Report

Nov 10, 2026

Estimate for Q3 26 (Revenue/ EPS)

-$0.13

Implied change from Q2 26 (Revenue/ EPS)

+18.18%

Implied change from Q3 25 (Revenue/ EPS)

-13.33%

Gain Therapeutics, Inc. Common Stock earnings per share and revenue

On Aug 11, 2026, GANX reported earnings of -0.11 USD per share (EPS) for Q2 26, beating the estimate of -0.14 USD, resulting in a 24.03% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +16.38% price change (close before vs. close after earnings).

Looking ahead to Q3 26, 6 analysts forecast an EPS of -0.13 USD, with revenue projected to reach -- USD, implying an increase of 18.18% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Champions Oncology, Inc.

Report Date

Sep 10, 2026 For Q1 27

Estimate

-$0.01

Actual

-$0.03

Surprise

-194.12%

PharmaCyte Biotech, Inc. Common Stock

Report Date

Sep 14, 2026 For Q1 27

Estimate

Actual

-$0.54

Surprise

FAQ

What were Gain Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Gain Therapeutics, Inc. Common Stock reported EPS of -$0.11, beating estimates by 24.03%, and revenue of $0.00, 0% as expectations.

How did the market react to Gain Therapeutics, Inc. Common Stock's Q2 2026 earnings?

The stock price moved up 16.38%, changed from $1.77 before the earnings release to $2.06 the day after.

When is Gain Therapeutics, Inc. Common Stock expected to report next?

The next earning report is scheduled for Nov 10, 2026.

What are the forecasts for Gain Therapeutics, Inc. Common Stock's next earnings report?

Based on 6 analysts, Gain Therapeutics, Inc. Common Stock is expected to report EPS of -$0.13 and revenue of -- for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.